- Home
- INZY vs NRO Comparison
INZY vs NRO Comparison
Compare INZY & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- NRO
- Stock Information
- Founded
- INZY 2015
- NRO 2003
- Country
- INZY United States
- NRO United States
- Employees
- INZY N/A
- NRO N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- NRO Finance/Investors Services
- Sector
- INZY Health Care
- NRO Finance
- Exchange
- INZY Nasdaq
- NRO Nasdaq
- Market Cap
- INZY 188.2M
- NRO 160.6M
- IPO Year
- INZY 2020
- NRO N/A
- Fundamental
- Price
- INZY $1.25
- NRO $3.35
- Analyst Decision
- INZY Strong Buy
- NRO
- Analyst Count
- INZY 8
- NRO 0
- Target Price
- INZY $17.75
- NRO N/A
- AVG Volume (30 Days)
- INZY 677.6K
- NRO 239.4K
- Earning Date
- INZY 03-11-2025
- NRO 01-01-0001
- Dividend Yield
- INZY N/A
- NRO 11.41%
- EPS Growth
- INZY N/A
- NRO N/A
- EPS
- INZY N/A
- NRO N/A
- Revenue
- INZY N/A
- NRO N/A
- Revenue This Year
- INZY N/A
- NRO N/A
- Revenue Next Year
- INZY N/A
- NRO N/A
- P/E Ratio
- INZY N/A
- NRO N/A
- Revenue Growth
- INZY N/A
- NRO N/A
- 52 Week Low
- INZY $1.24
- NRO $2.51
- 52 Week High
- INZY $7.80
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- INZY 31.42
- NRO 45.59
- Support Level
- INZY $1.24
- NRO $3.32
- Resistance Level
- INZY $1.43
- NRO $3.37
- Average True Range (ATR)
- INZY 0.10
- NRO 0.06
- MACD
- INZY 0.04
- NRO 0.01
- Stochastic Oscillator
- INZY 3.12
- NRO 52.63
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").